Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume -, Issue -, Pages 1-8
Publisher
Informa UK Limited
Online
2019-04-24
DOI
10.1080/10428194.2019.1602268
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound
- (2018) Joshua N. Gustine et al. AMERICAN JOURNAL OF HEMATOLOGY
- Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis
- (2018) Sameer A. Parikh et al. HAEMATOLOGICA
- Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia
- (2018) Jorge J. Castillo et al. HAEMATOLOGICA
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
- (2018) Jeffrey A Jones et al. LANCET ONCOLOGY
- Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis
- (2018) Sameer A. Parikh et al. HAEMATOLOGICA
- Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia
- (2018) Jorge J. Castillo et al. HAEMATOLOGICA
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
- (2017) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ONCOLOGY
- Disease flare after discontinuing gefitinib in a patient with lung adenocarcinoma and concomitant epithelial growth factor receptor mutation and anaplastic lymphoma kinase translocation
- (2017) Eun Hye Park et al. Journal of Thoracic Disease
- Chemotherapy Significantly Improves Survival for Patients with T1c-T2N0M0 Medullary Breast Cancer: 3739 Cases From the National Cancer Data Base
- (2016) Alina M. Mateo et al. ANNALS OF SURGICAL ONCOLOGY
- Setdb1 maintains hematopoietic stem and progenitor cells by restricting the ectopic activation of nonhematopoietic genes
- (2016) S. Koide et al. BLOOD
- Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience
- (2016) A. R. Mato et al. BLOOD
- Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
- (2016) HAEMATOLOGICA
- Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)
- (2016) Tait D. Shanafelt et al. LEUKEMIA & LYMPHOMA
- Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
- (2016) HAEMATOLOGICA
- Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
- (2015) P. Jain et al. BLOOD
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
- (2015) Kami J. Maddocks et al. JAMA Oncology
- Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
- (2014) Yan Beauverd et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Definition and management of ruxolitinib treatment failure in myelofibrosis
- (2014) A Pardanani et al. Blood Cancer Journal
- Ruxolitinib Withdrawal Syndrome Leading to Tumor Lysis
- (2013) Tong Dai et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib
- (2012) Oana Pop et al. Journal of Thoracic Oncology
- Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial
- (2010) Axel Le Cesne et al. LANCET ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started